Theodore James Jr. Washburn - 01 Aug 2021 Form 3 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role
Principal Accounting Officer
Signature
/s/ William Cook, as attorney-in-fact for Theodore James Jr. Washburn
Issuer symbol
AGIO
Transactions as of
01 Aug 2021
Net transactions value
$0
Form type
3
Filing time
05 Aug 2021, 16:16:39 UTC
Next filing
14 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AGIO Common stock 2,515 01 Aug 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AGIO Stock options (right to buy) 01 Aug 2021 Common stock 5,000 $51.20 Direct F1
holding AGIO Stock options (right to buy) 01 Aug 2021 Common stock 2,022 $77.70 Direct F2
holding AGIO Stock options (right to buy) 01 Aug 2021 Common stock 2,000 $58.86 Direct F3
holding AGIO Stock options (right to buy) 01 Aug 2021 Common stock 540 $51.51 Direct F4
holding AGIO Stock options (right to buy) 01 Aug 2021 Common stock 1,165 $56.68 Direct F5
holding AGIO Restricted stock units 01 Aug 2021 Common stock 167 Direct F6, F7
holding AGIO Restricted stock units 01 Aug 2021 Common stock 720 Direct F7, F8
holding AGIO Restricted stock units 01 Aug 2021 Common stock 2,331 Direct F7, F9
holding AGIO Restricted stock units 01 Aug 2021 Common stock 4,150 Direct F7, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on May 1, 2017. The shares underlying this option are fully vested.
F2 This option was granted on February 16, 2018. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F3 This option was granted on February 22, 2019. The shares underlying this option vest as to 25% of the underlying shares on February 22, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F4 This option was granted on February 14, 2020. The shares underlying this option vest as to 25% of the underlying shares on February 14, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F5 This option was granted on February 10, 2021. The shares underlying this option vest as to 25% of the underlying shares on February 10, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F6 The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments.
F7 Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F8 The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments.
F9 The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments.
F10 The restricted stock units were granted on August 1, 2021. The shares underlying the stock units will vest in full on August 1, 2023.